Biopharmaceutical News and Research

RSS

Amgen Plans R&D Center In China

...

25 Sep 2013

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today that it has been awarded a contract valued at up to $6.4 million by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

25 Sep 2013

BioLineRx announces regulatory submissions to commence Phase 1/2 trial for treatment of celiac disease

BioLineRx, a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a Phase 1/2 trial for BL-7010 - for the treatment of celiac disease - with the Finnish National Supervisory Authority for Welfare and Health (Valvira). The relevant ethics committee has already approved commencement of the study.

24 Sep 2013

Packaging Coordinators, Inc., to exhibit service offerings at CPhI 2013

Packaging Coordinators, Inc. (PCI), a global supplier of pharmaceutical commercial packaging solutions and clinical trials services is pleased to announce that it will be exhibiting its full range of services on booth 41M15 at CPhI Worldwide. Exhibiting for the first time as Packaging Coordinators, inc. since May 2013 when AndersonBrecon merged with and operated as Frazier Healthcare’s portfolio company, PCI, the company is now one of the largest suppliers of packaging supply services to the pharmaceutical industry and will be demonstrating its capabilities in clinical trials, in laboratory services and commercial services for pharmaceutical and biopharmaceutical customers.

From Packaging Coordinators Inc. (PCI) 23 Sep 2013

Study sheds light on investment levels across 12 key marketing, education and payer activities

In order for a new product to gain a foothold in today's competitive pharmaceutical market, executives must understand where and when to invest in key launch activities. At the same time, product launch leaders have to balance the goals of containing expenditures and generating a successful launch.

21 Sep 2013

Ventana, Boehringer Ingelheim to develop companion diagnostic tests for oncology programs

Ventana Medical Systems, Inc., a member of the Roche Group, and Boehringer Ingelheim announced today that they have entered into an agreement to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim oncology programs.

19 Sep 2013

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

SignaBlok, Inc., a Massachusetts-based biopharmaceutical company, today announced the successful in vivo proof of concept data that demonstrate that the company's novel mechanism-based, first-in-class peptide inhibitor of TREM-1 effectively suppresses cancer progression in mouse models of lung cancer and dramatically improves survival in septic mice.

18 Sep 2013

Regado Biosciences announces enrollment of first patient in REGULATE-PCI clinical trial

Regado Biosciences, Inc., a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications, today announced the enrollment of the first patient in its REGULATE-PCI clinical trial.

17 Sep 2013

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.

16 Sep 2013

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient SGX94 for the treatment of acute radiation syndrome (ARS).

16 Sep 2013

Circassia: House dust mite allergy treatment meets primary endpoint in phase II clinical study

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful results from a phase II clinical study of its house dust mite allergy treatment (House Dust Mite-Synthetic Peptide Immuno-Regulatory Epitope [HDM-SPIRE] based on Circassia’s ToleroMune technology).

12 Sep 2013

Kiadis five-year follow-up phase I/II clinical study confirms long-term safety, efficacy of ATIR

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that the five-year follow-up of patients with high-risk malignancies from its Phase I/II clinical study confirms long-term safety and efficacy of ATIR™ over a broad dose range.

12 Sep 2013

Ventana gets CFDA approval for VENTANA ALK immunohistochemistry assay

Ventana Medical Systems, Inc., a member of the Roche Group, today announced the approval of the VENTANA ALK immunohistochemistry assay by the Chinese Food and Drug Administration as a companion diagnostic to aid in the identification of patients for Pfizer's CFDA-approved oncology product XALKORI (crizotinib).

12 Sep 2013

Berg receives Drug Discovery Technology Innovation Award for agnostic approach to drug discovery

Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach, was recognized today with the 2013 North American Drug Discovery Technology Innovation Award at the Frost & Sullivan Growth, Innovation and Leadership Awards Gala, the annual event by the global research organization that highlights the most promising new innovative technology across sectors.

12 Sep 2013

Developing Analytical Techniques for Biotherapeutics

News-Medical talks to Dr. Lewis about the development of analytical equipment for a new era of drug development that goes beyond small molecule synthesis.

From Malvern Panalytical 11 Sep 2013

Paragon Bioservices awarded 2013 CMO Leadership Award for Quality and Reliability

Paragon Bioservices, a contract manufacturing organization whose expertise is the process development and manufacturing of biopharmaceuticals, announced today that it has been awarded the 2013 CMO Leadership Award for Quality and Reliability.

10 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

$Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma$

Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

The Lancet Oncology published this week findings from a study, which showed that the new oral therapy IMNOVID®▼ (pomalidomide), used in combination with low-dose dexamethasone demonstrated a significant survival advantage over high-dose dexamethasone alone, in patients with relapsed and refractory multiple myeloma (rrMM).1

5 Sep 2013

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

ThromboGenics NV, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that it has entered into a collaboration and license agreement with Bicycle Therapeutics to develop and commercialize novel drugs inhibiting a specific target for the treatment of ophthalmic diseases, such as diabetic macular edema.

5 Sep 2013

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or "bad cholesterol").

4 Sep 2013

Biopharmaceutical News and Research

Amgen Plans R&D Center In China

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

BioLineRx announces regulatory submissions to commence Phase 1/2 trial for treatment of celiac disease

Packaging Coordinators, Inc., to exhibit service offerings at CPhI 2013

Study sheds light on investment levels across 12 key marketing, education and payer activities

Ventana, Boehringer Ingelheim to develop companion diagnostic tests for oncology programs

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

Regado Biosciences announces enrollment of first patient in REGULATE-PCI clinical trial

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome

Circassia: House dust mite allergy treatment meets primary endpoint in phase II clinical study

Kiadis five-year follow-up phase I/II clinical study confirms long-term safety, efficacy of ATIR

Ventana gets CFDA approval for VENTANA ALK immunohistochemistry assay

Berg receives Drug Discovery Technology Innovation Award for agnostic approach to drug discovery

Developing Analytical Techniques for Biotherapeutics

Paragon Bioservices awarded 2013 CMO Leadership Award for Quality and Reliability

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News